| Martinez, Eduardo |
| Completed | 4 | 3460 | US, RoW | Enoxaparin, Apixaban | Valentin Fuster | COVID-19, SARS-CoV-2 | 12/22 | 12/22 | | |
| Recruiting | 3 | 612 | Europe, Canada, Japan, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 03/25 | 04/25 | | |
NCT06261957: A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma |
|
|
| Recruiting | 3 | 412 | Europe, Canada, US, RoW | Salbutamol HFA-134a, Salbutamol HFA-152a | GlaxoSmithKline | Asthma | 04/25 | 04/25 | | |
| Recruiting | 3 | 1050 | Europe, Canada, Japan, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 01/26 | 01/30 | | |
| Recruiting | 3 | 1063 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis | 07/26 | 12/27 | | |
|
| Active, not recruiting | 2 | 162 | Europe | Abemaciclib, Verzenios, Paclitaxel, Paclitaxel Teva, Letrozole, Fulvestrant | MedSIR, Eli Lilly and Company | Breast Cancer Metastatic | 06/24 | 06/25 | | |
| Completed | 2 | 73 | Europe | Palbociclib, Ibrance, Trastuzumab, Herceptin, Endocrine therapy, ET, Chemotherapy, CT, Antibody-Drug Conjugates, Trastuzumab emtansine (TDM-1) | SOLTI Breast Cancer Research Group | Metastatic Breast Cancer | 09/23 | 11/23 | | |
METALLICA, NCT04300790: Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients |
|
|
| Active, not recruiting | 2 | 69 | Europe | Alpelisib, BYL719, Metformin, Fulvestrant, Letrozole, Exemestane, Vildagliptin, Tamoxifen | MedSIR, Novartis | Breast Cancer | 03/25 | 06/26 | | |
| Active, not recruiting | 2 | 393 | Europe | Trastuzumab and Pertuzumab (FDC SC) and T-DM1, Trastuzumab emtansine, Phesgo, Kadcyla | MedSIR, Hoffmann-La Roche | Early Breast Cancer | 09/25 | 03/28 | | |
| Holderman, William |
NCT06045754: A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease |
|
|
| Recruiting | 4 | 150 | Canada, US | Vedolizumab, Entyvio, Adalimumab, Humira, Ustekinumab, Stelara | Takeda | Crohn's Disease | 06/27 | 06/27 | | |
NCT06095128: A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC) |
|
|
| Recruiting | 4 | 65 | Canada, US | Vedolizumab, Entyvio, MLN0002, Tofacitinib, Xeljanz, CP-690, CP-550 | Takeda | Ulcerative Colitis | 07/27 | 07/27 | | |
LUCENT-URGE, NCT05767021: A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis |
|
|
| Active, not recruiting | 3 | 160 | Europe, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis, Ulcerative Colitis Chronic | 08/24 | 09/25 | | |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 11/24 | 12/26 | | |
| Recruiting | 3 | 1063 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis | 07/26 | 12/27 | | |
|
ALTUS, NCT05064553: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk |
|
|
| Recruiting | N/A | 2500 | US | Study CT/MRI Imaging, Standard of Care CT/MRI Imaging, Oncoguard™ Liver Test | Exact Sciences Corporation | Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatitis B, Cirrhosis, Liver Cancer | 01/25 | 04/26 | | |
| Yan, Peng |
| Completed | 3 | 1281 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828, Placebo | Eli Lilly and Company | Ulcerative Colitis | 01/21 | 05/24 | | |
|
|
|
|
| Completed | 3 | 1177 | Europe, Canada, Japan, US, RoW | Mirikizumab SC, LY3074828, Mirikizumab IV, Placebo SC | Eli Lilly and Company | Ulcerative Colitis | 11/21 | 12/24 | | |
|
|
NCT05181137 / 2021-001940-86: A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis |
|
|
| Recruiting | 3 | 368 | Europe, US, RoW | SHR0302, Placebo | Reistone Biopharma Company Limited, Reistone Biopharma Company Limited | Ulcerative Colitis | 10/24 | 03/25 | | |
| Recruiting | 3 | 1063 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis | 07/26 | 12/27 | | |
|
| Zhang, Guoxin |
NCT03825692: International Clinical Study of Zhizhu Kuanzhong Capsule |
|
|
| Recruiting | 4 | 480 | RoW | Zhizhu Kuanzhong Capsule, ZZKZ capsule, Zhizhu Kuanzhong Placebo Capsule, placebo | Xiyuan Hospital of China Academy of Chinese Medical Sciences | Functional Dyspepsia, Postprandial Distress Syndrome | 12/23 | 12/23 | | |
| Completed | 3 | 1281 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828, Placebo | Eli Lilly and Company | Ulcerative Colitis | 01/21 | 05/24 | | |
|
|
|
|
| Completed | 3 | 1177 | Europe, Canada, Japan, US, RoW | Mirikizumab SC, LY3074828, Mirikizumab IV, Placebo SC | Eli Lilly and Company | Ulcerative Colitis | 11/21 | 12/24 | | |
|
|
| Recruiting | 3 | 1063 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis | 07/26 | 12/27 | | |
|
NCT03221036: Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis |
|
|
| Recruiting | 3 | 402 | RoW | Vedolizumab IV, Placebo | Takeda | Moderately to Severely Active Ulcerative Colitis | 05/28 | 07/28 | | |
NCT04639323: Endoscopic Ruler for the Assessment of Variceal Bleeding Risks (CHESS2005) |
|
|
| Recruiting | N/A | 266 | RoW | Endoscopic ruler | Hepatopancreatobiliary Surgery Institute of Gansu Province, LanZhou University, Tianjin Second People's Hospital, The First Affiliated Hospital with Nanjing Medical University, People's Hospital of Ningxia Hui Autonomous Region, The Second Affiliated Hospital of Baotou Medical College, The Third Xiangya Hospital of Central South University, The Second Hospital of Hebei Medical University, The Affiliated Hospital Of Southwest Medical University, First Hospital of China Medical University | Liver Cirrhosis, Portal Hypertension, Gastroesophageal Varices | 04/23 | 01/25 | | |
| Wang, Dongming |
| Completed | 3 | 1281 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828, Placebo | Eli Lilly and Company | Ulcerative Colitis | 01/21 | 05/24 | | |
|
|
|
|
| Completed | 3 | 1177 | Europe, Canada, Japan, US, RoW | Mirikizumab SC, LY3074828, Mirikizumab IV, Placebo SC | Eli Lilly and Company | Ulcerative Colitis | 11/21 | 12/24 | | |
|
|
| Recruiting | 3 | 1063 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis | 07/26 | 12/27 | | |
|
| Song, Zhengji |
| Completed | 3 | 1281 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828, Placebo | Eli Lilly and Company | Ulcerative Colitis | 01/21 | 05/24 | | |
|
|
|
|
| Completed | 3 | 1177 | Europe, Canada, Japan, US, RoW | Mirikizumab SC, LY3074828, Mirikizumab IV, Placebo SC | Eli Lilly and Company | Ulcerative Colitis | 11/21 | 12/24 | | |
|
|
| Recruiting | 3 | 1063 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis | 07/26 | 12/27 | | |
|
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
NCT05837897: A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease |
|
|
| Recruiting | 3 | 408 | RoW | Vedolizumab IV, Placebo | Takeda | Crohn's Disease | 03/30 | 05/31 | | |
| Chen, Chunxiao |
| Completed | 3 | 1281 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828, Placebo | Eli Lilly and Company | Ulcerative Colitis | 01/21 | 05/24 | | |
|
|
|
|
| Completed | 3 | 1177 | Europe, Canada, Japan, US, RoW | Mirikizumab SC, LY3074828, Mirikizumab IV, Placebo SC | Eli Lilly and Company | Ulcerative Colitis | 11/21 | 12/24 | | |
|
|
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 03/25 | 04/25 | | |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 11/24 | 12/26 | | |
| Recruiting | 3 | 1050 | Europe, Canada, Japan, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 01/26 | 01/30 | | |
| Recruiting | 3 | 1063 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis | 07/26 | 12/27 | | |
|
NCT05837897: A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease |
|
|
| Recruiting | 3 | 408 | RoW | Vedolizumab IV, Placebo | Takeda | Crohn's Disease | 03/30 | 05/31 | | |
NCT03977480: Phase II Study of Hemay007 in Patients With Active Ulcerative Colitis |
|
|
| Terminated | 2 | 70 | RoW | Hemay007, Placebo | Tianjin Hemay Pharmaceutical Co., Ltd | Ulcerative Colitis | 08/22 | 08/22 | | |
NCT05770609: A Study of SPH3127 in the Treatment of Mild to Moderate Ulcerative Colitis |
|
|
| Recruiting | 2 | 108 | RoW | SPH3127 Tablets with Dose A, SPH3127 Tablets with Dose B, SPH3127 Tablets placebo | Shanghai Pharmaceuticals Holding Co., Ltd | Mild to Moderate Ulcerative Colitis | 02/25 | 02/25 | | |
| Liu, Xiaowei |
UplighTED, NCT06307613: A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults with Thyroid Eye Disease |
|
|
| Recruiting | 3 | 108 | Europe, US, RoW | Efgartigimod PH20 SC, Placebo PH20 SC | argenx | Thyroid Eye Disease | 02/26 | 10/27 | | |
| Not yet recruiting | 3 | 420 | RoW | Anlotinib hydrochloride capsule + TQB2450 injection, Chemotherapy drug | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Endometrial Cancer | 12/27 | 06/29 | | |
NCT06717152: Efficacy and Safety of SJP-0132 Eye Drops in Chinese Patients With Dry Eye Disease |
|
|
| Recruiting | 3 | 400 | RoW | SJP-0132, Placebo | Senju Pharmaceutical Science & Technology (Beijing) Co., Ltd., Senju Pharmaceutical Co., Ltd. | Dry Eye | 07/25 | 08/25 | | |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 11/24 | 12/26 | | |
NCT04531475: Study to Evaluate the Safety and Efficacy of X842 in Patients With Reflux Esophagitis |
|
|
| Recruiting | 2 | 90 | RoW | X842, Undecided, X842 Placebo, Lansoprazole, Lansoprazole Placebo | Jiangsu Sinorda Biomedicine Co., Ltd | Reflux Esophagitis | 10/20 | 12/20 | | |
NCT03977480: Phase II Study of Hemay007 in Patients With Active Ulcerative Colitis |
|
|
| Terminated | 2 | 70 | RoW | Hemay007, Placebo | Tianjin Hemay Pharmaceutical Co., Ltd | Ulcerative Colitis | 08/22 | 08/22 | | |
NCT05486104: Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis |
|
|
| Recruiting | 2 | 108 | RoW | Hemay005 tablets, Hemay005 45 mg BID group, Hemay005 placebo tablets, Hemay005 placebo BID group | Ganzhou Hemay Pharmaceutical Co., Ltd | Moderate to Severe Ulcerative Colitis | 06/24 | 09/24 | | |
TQH3906-Ib-01, NCT06754891: Clinical Trial of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease |
|
|
| Not yet recruiting | 1 | 116 | RoW | TQH3906 capsules | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Inflammatory Bowel Diseases | 12/26 | 12/27 | | |
NCT05718193: Real-Time Artificial Intelligence Assissted Colonoscopy to Identify and Classify Polyps |
|
|
| Completed | N/A | 2868 | RoW | DeFrame, Classified DeFrame, conventional colonoscopy | Xiangya Hospital of Central South University, Loudi Central Hospital | Artificial Intelligence, Colonoscopy, Quality Control | 02/23 | 03/23 | | |
NCT05941689: Efficacy of Artificial Intelligence-assisted Colonic Polyp Detection System |
|
|
| Completed | N/A | 1906 | RoW | AI-assisted colonoscopy | Xiangya Hospital of Central South University | Adenoma Colon | 09/23 | 09/23 | | |
NCT04872491: A Study of Vedolizumab in Adults in Real-World Practice |
|
|
| Completed | N/A | 500 | RoW | | Takeda | Colitis, Ulcerative, Crohn Disease | 07/24 | 07/24 | | |
| ZHENG, Chang Qing |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 11/24 | 12/26 | | |
| Recruiting | 3 | 1063 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis | 07/26 | 12/27 | | |
|
| Samanta, Jayanta |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 11/24 | 12/26 | | |
| Recruiting | N/A | 81 | US, RoW | POEM-F, Conventional POEM | Chinese University of Hong Kong, Deenanath Mangeshkar Hospital and Research Centre, Johns Hopkins University, Northwestern University Feinberg School of Medicine, Nanfang Hospital, Southern Medical University, Asian Institute of Gastroenterology, India, Post Graduate Institute of Medical Education and Research, Chandigarh | Achalasia | 10/25 | 10/26 | | |
| Ozin, Yasemin |
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 03/25 | 04/25 | | |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 11/24 | 12/26 | | |
| LIU, Wenjia |
| Completed | 3 | 1177 | Europe, Canada, Japan, US, RoW | Mirikizumab SC, LY3074828, Mirikizumab IV, Placebo SC | Eli Lilly and Company | Ulcerative Colitis | 11/21 | 12/24 | | |
|
|
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 03/25 | 04/25 | | |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 11/24 | 12/26 | | |
| Recruiting | 3 | 1050 | Europe, Canada, Japan, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 01/26 | 01/30 | | |
| Recruiting | 3 | 1063 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis | 07/26 | 12/27 | | |
|
NCT05837897: A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease |
|
|
| Recruiting | 3 | 408 | RoW | Vedolizumab IV, Placebo | Takeda | Crohn's Disease | 03/30 | 05/31 | | |
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis |
|
|
| Recruiting | 2 | 207 | Europe, Canada, Japan, US, RoW | TAK-279, Zasocitinib, Placebo | Takeda | Ulcerative Colitis | 09/26 | 08/27 | | |
| Marinovic, Slobodanka Crevar |
| Recruiting | 3 | 612 | Europe, Canada, Japan, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 03/25 | 04/25 | | |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 11/24 | 12/26 | | |
| Recruiting | 3 | 1050 | Europe, Canada, Japan, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 01/26 | 01/30 | | |
| Chiang, Dian |
ALTUS, NCT05064553: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk |
|
|
| Recruiting | N/A | 2500 | US | Study CT/MRI Imaging, Standard of Care CT/MRI Imaging, Oncoguard™ Liver Test | Exact Sciences Corporation | Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatitis B, Cirrhosis, Liver Cancer | 01/25 | 04/26 | | |
